Trichomoniasis: Treatment and Partner Management

Clinical recognition and testing

Trichomonas vaginalis may cause malodorous vaginal discharge, vulvovaginal irritation, dysuria, or cervicitis, but infection is frequently asymptomatic. Men may present with urethritis or be asymptomatic carriers. A nucleic acid amplification test (NAAT) is more sensitive than wet-mount microscopy; a negative wet mount does not exclude infection. Evaluate pregnancy status, possible pelvic inflammatory disease, and concurrent gonorrhea, chlamydia, syphilis, and HIV where indicated (Smith & Honeywell, 2026).

Drug regimens

For women, metronidazole 500 mg orally twice daily for seven days is preferred. For men, metronidazole 2 g orally once remains a recommended regimen. Tinidazole 2 g orally once is an alternative for eligible adults of either sex. Intravaginal metronidazole gel is not a substitute for oral treatment because it does not adequately reach all infected sites. Review gastrointestinal intolerance, allergies, drug interactions, and pregnancy or breastfeeding factors before treatment (Smith & Honeywell, 2026).

Partner treatment and counseling

Current sexual partners should receive appropriate treatment, even if asymptomatic. Advise abstaining from intercourse until both the patient and partners complete treatment and symptoms resolve. Use nonjudgmental sexual history taking and consider available partner-treatment mechanisms under local law. For sexually active women, retest approximately three months after treatment because reinfection is frequent; routine retesting in men is not established in the same way (Smith & Honeywell, 2026).

Persistent or recurrent infection

First distinguish reinfection from medication nonadherence or true antimicrobial resistance. Ask whether partners completed treatment and whether exposure occurred during therapy. When repeat NAAT is used to evaluate persistence, avoid testing so early that residual nucleic acids create a false-positive result; waiting at least three weeks after completion is generally appropriate. Persistent infection without re-exposure can require higher-dose regimens and expert-guided susceptibility evaluation (Smith & Honeywell, 2026).

Pregnancy and clinical context

Symptomatic pregnant patients warrant treatment and counseling because untreated infection can be associated with adverse pregnancy outcomes. Select the regimen through pregnancy-specific recommendations and discuss breastfeeding considerations for a high single dose of tinidazole or metronidazole. Avoid presenting all vaginal discharge as either candidiasis or BV without diagnostic evidence.

Compared with BV and candidiasis

The presence of trichomoniasis changes partner management: current partners should receive treatment, unlike routine partner treatment for uncomplicated candidiasis. Topical metronidazole used for BV is not sufficient for trichomoniasis. No empirical vaginal-discharge regimen should be chosen solely on the basis of discharge appearance when diagnostic testing is available (Smith & Honeywell, 2026).

What to do after a repeat positive test

For women, initial oral metronidazole 500 mg twice daily for seven days differs from the single 2-g regimen often used in men. A second positive test is not immediately evidence of resistance: confirm whether all partners were treated, when sex resumed, adherence, and whether NAAT was collected too soon after treatment. Re-exposure generally points toward retreatment with an appropriate standard regimen and partner services; verified persistence without re-exposure calls for an escalation pathway and, when necessary, expert susceptibility guidance rather than repeated intravaginal gel (Smith & Honeywell, 2026).

Manage intolerance and co-infection deliberately

Review a reported metronidazole allergy carefully, since intolerance and immediate hypersensitivity require different plans. Pregnant patients with symptoms should receive an evidence-supported regimen and counseling; breastfeeding precautions vary by drug and single versus divided dosing. Screen for related STIs by exposure and symptoms. Persistent vaginal discharge with negative repeat T. vaginalis testing should redirect the differential toward BV, yeast, or cervicitis rather than another empiric high-dose nitroimidazole course (Smith & Honeywell, 2026).

Clinical application

A nonpregnant woman returns with a positive NAAT six weeks after completing a seven-day metronidazole course. Her partner was untreated and intercourse resumed soon afterward. Reinfection is more likely than microbiologic resistance: arrange appropriate retreatment, partner services, counseling, and three-month retesting. By contrast, persistent positivity without re-exposure after a correctly taken regimen requires expert-guided alternative treatment assessment. An NAAT performed within three weeks of therapy could be misleading because of residual nucleic acid (CDC, 2021, Trichomoniasis; Smith & Honeywell, 2026).

High-yield distinctions

Metronidazole 500 mg twice daily for seven days is the preferred regimen for women; single-dose 2 g is standard for men. Partner treatment is essential. Intravaginal gel is not adequate trichomoniasis therapy.

Related YourDNP Resources

Pharmacology learning hub · Bacterial vaginosis · Gonorrhea · Pelvic inflammatory disease

---

---

References

Centers for Disease Control and Prevention. (2021). Trichomoniasis. https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm

Smith, U. D., & Honeywell, M. S. (2026). Sexually transmitted infections. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 83). McGraw Hill.